InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.065 0.063 (3,150%)+
Announcement
Release
27 Apr 2026 9:15AM
Price at Release
$0.002
Full Release
download
Summary
Chimeric Therapeutics Limited, an Australian leader in cell therapy, announced that their CHM CORE-NK Phase 1B clinical trial achieved a 60% Complete Response/Complete Response with Incomplete count recovery (CR/CRi) in 25 enrolled high-risk, frontline subjects with acute myeloid leukemia (AML). The trial, part of the ADVENT-AML study, is conducted at The University of Texas MD Anderson Cancer Center and combines CHM CORE-NK with azacitidine and venetoclax. The treatment has been well tolerated with no unexpected safety issues. This represents a significant improvement over the typical 20-30% response rate seen with the current standard of care. The trial is an investigator-initiated study evaluating the synergy of NK cell therapy in combination with existing treatments.
Key Points
  • 60% CR/CRi achieved in 25 enrolled patients
  • Trial conducted at University of Texas MD Anderson Cancer Center
  • Combination of CHM CORE-NK with azacitidine and venetoclax
  • Well-tolerated treatment with no unexpected safety issues
  • Investigator-initiated study
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.